JP2019532092A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532092A5
JP2019532092A5 JP2019522803A JP2019522803A JP2019532092A5 JP 2019532092 A5 JP2019532092 A5 JP 2019532092A5 JP 2019522803 A JP2019522803 A JP 2019522803A JP 2019522803 A JP2019522803 A JP 2019522803A JP 2019532092 A5 JP2019532092 A5 JP 2019532092A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
heteroatoms selected
substituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522803A
Other languages
English (en)
Japanese (ja)
Other versions
JP7145850B2 (ja
JP2019532092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058645 external-priority patent/WO2018081488A1/en
Publication of JP2019532092A publication Critical patent/JP2019532092A/ja
Publication of JP2019532092A5 publication Critical patent/JP2019532092A5/ja
Application granted granted Critical
Publication of JP7145850B2 publication Critical patent/JP7145850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522803A 2016-10-28 2017-10-27 Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物 Active JP7145850B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662414158P 2016-10-28 2016-10-28
US62/414,158 2016-10-28
PCT/US2017/058645 WO2018081488A1 (en) 2016-10-28 2017-10-27 Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (3)

Publication Number Publication Date
JP2019532092A JP2019532092A (ja) 2019-11-07
JP2019532092A5 true JP2019532092A5 (enExample) 2020-11-12
JP7145850B2 JP7145850B2 (ja) 2022-10-03

Family

ID=60263169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522803A Active JP7145850B2 (ja) 2016-10-28 2017-10-27 Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物

Country Status (8)

Country Link
US (1) US10781215B2 (enExample)
EP (1) EP3532473B1 (enExample)
JP (1) JP7145850B2 (enExample)
KR (1) KR102477063B1 (enExample)
CN (1) CN110114357B (enExample)
ES (1) ES2895107T3 (enExample)
MA (1) MA46620A (enExample)
WO (1) WO2018081488A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
AR117177A1 (es) * 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
CN113874021B (zh) * 2019-03-26 2024-07-09 温缇克斯生物科学公司 Tyk2假激酶配体
CN114269336A (zh) 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
AU2020378345A1 (en) 2019-11-08 2022-06-02 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
US11697648B2 (en) * 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
CN116283993B (zh) * 2021-12-20 2024-05-03 艾立康药业股份有限公司 一种嘧啶类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
ES2424977T3 (es) 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
KR101238585B1 (ko) * 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
SG11201503395TA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
CN105992768B (zh) * 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
RU2016148863A (ru) 2014-05-14 2018-06-18 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт Гетероциклические гидроксамовые кислоты в качестве ингибиторов протеин-деацетилазы и двойных ингибиторов протеин-деацетилазы-протеин-киназы и способы их применения
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019532092A5 (enExample)
JP2019530699A5 (enExample)
JP2017511357A5 (enExample)
JP2015514806A5 (enExample)
JP2019518766A5 (enExample)
JP2015514808A5 (enExample)
JP2016536363A5 (enExample)
JP2016536364A5 (enExample)
JP2016534134A5 (enExample)
JP2018529739A5 (enExample)
JP2019081762A5 (enExample)
JP2016532715A5 (enExample)
JP2016501185A5 (enExample)
JP2015535277A5 (enExample)
JP2016506369A5 (enExample)
JP2016518328A5 (enExample)
JP2016506368A5 (enExample)
JP2012140432A5 (enExample)
JP2017535614A5 (enExample)
JP2020502268A5 (enExample)
JP2008505194A5 (enExample)
JP2017501237A5 (enExample)
JP2016040262A5 (enExample)
RU2020131276A (ru) Терапевтические соединения и композиции
JP2016531868A5 (enExample)